Syntara’s SNT-5505 Shows Promising Phase 2 Results, Secures A$15M Funding Boost

• Positive interim Phase 2 data for SNT-5505 in myelofibrosis with symptom and spleen volume improvements
• No treatment-related serious adverse events reported in combination with JAK inhibitor ruxolitinib
• A$15 million capital raising completed via two-tranche placement to fund clinical trials and operations
• Strong cash position of A$18.1 million at December quarter end, pro forma A$20.7 million including tranche 2